Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma

Tomer M Mark, MD MSc, Peter Forsberg, MD, Ihsane Ouansafi, MD, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Morton Coleman, MD, David Jayabalan, BSMS, MSc, Ruben Niesvizky, MD, Scott A Ely, MD MPH

Blood (2014) 124 (21): 2016.

https://doi.org/10.1182/blood.V124.21.2016.2016

Published: 2014

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Angelique Boyer, Adriana C Rossi, MD, Dennis Kwon, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1955.

https://doi.org/10.1182/blood.V122.21.1955.1955

Published: 2013

Journal Articles

The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

Peter Martin, MD, Maurizio DiLiberto, PhD, Christopher E Mason, PhD, Scott A Ely, M.D., Jia Ruan, MD, PhD, Richard R. Furman, MD, David Chiron, PhD, Xiangao Huang, PhD, David C Madoff, M.D., Jonathan Navi, Jessica Lewis, PA-C, Alison Bender, PA-C, Amelyn Rodriguez, RN, June Greenberg, RN, Morton Coleman, MD, Selina Chen-Kiang, PhD, John P. Leonard, M.D.

Blood (2013) 122 (21): 4393.

https://doi.org/10.1182/blood.V122.21.4393.4393

Published: 2013

Journal Articles

Car-Bird [Carfilzomib, Clarithromycin(Biaxin (R) ), Lenalidomide/(Revlimid (R) ), Dexamethasone) For Newly-Diagnosed Multiple Myeloma

Tomer M Mark, MD, MSc, John N. Allan, MD, Geoffrey Marano, Adriana C Rossi, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Linda Tegnestam, RN, Karen Pekle, NP, David Jayabalan, B.S.M.S, Morton Coleman, MD, Scott A Ely, MD, MPH, Ruben Niesvizky, MD

Blood (2013) 122 (21): 3216.

https://doi.org/10.1182/blood.V122.21.3216.3216

Published: 2013

Journal Articles

Integrative Whole Transcriptome and Exome Sequencing Reveals Reprogramming Of Mantle Cell Lymphoma In Prolonged Early G1 Arrest For Clinical Response To Selective Inhibition Of CDK4 In Combination Therapy

David Chiron, PhD, Peter Martin, MD, Maurizio Di Liberto, Ph.D., Xiangao Huang, PhD, Priyanka Vijay, B.A, Pedro Blecua, PhD, Scott A Ely, MD, MPH, Olivier Elemento, PhD, Christopher E Mason, PhD, John P. Leonard, MD, Selina Chen-Kiang, PhD

Blood (2013) 122 (21): 80.

https://doi.org/10.1182/blood.V122.21.80.80

Published: 2013

Journal Articles

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Angelique Boyer, Adriana C Rossi, MD, Manan Shah, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, Erlinda A Sacris, RN, June Greenberg, RN, Stephanie Speaker, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2012) 120 (21): 77.

https://doi.org/10.1182/blood.V120.21.77.77

Published: 2012

Journal Articles

Induction of Early G1-Arrest by CDK4/CDK6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to Selective PI3Kδ Inhibition by GS-1101 Through Enhancing the Magnitude and Duration of p-AKT Inhibition

David Chiron, PhD, Peter Martin, MD, Maurizio Di Liberto, Ph.D., Xiangao Huang, PhD, Scott A Ely, MD, MPH, Brian J. Lannutti, PhD, John P. Leonard, MD, Christopher E. Mason, PhD, Selina Chen-Kiang, PhD

Blood (2012) 120 (21): 791.

https://doi.org/10.1182/blood.V120.21.791.791

Published: 2012

Journal Articles

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

Blood (2012) 119 (20): 4597–4607.

https://doi.org/10.1182/blood-2011-10-388298

Published: 2012

Includes: Supplemental data

Journal Articles

ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Melissa Rodriguez, Manan Shah, Ryann Quinn, Jessica Campbell, Ramsey Abdullah, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Patrice Mignott, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 635.

https://doi.org/10.1182/blood.V118.21.635.635

Published: 2011

Journal Articles

Mutation Burden in CDKN2C, CDK1 and E2F2 Is Associated with Differential Response to Targeting CDK4/CDK6 in Combination with Bortezomib in Mantle Cell Lymphoma,

Christopher E. Mason, PhD, Maurizio Di Liberto, Ph.D., Xiangao Huang, PhD, David Chiron, PhD, Jamieson Bretz, Ph.D., Ramsey Abdallah, B.S., Scott A Ely, M.D., Daniel M Knowles, MD, Peter Martin, MD, John P. Leonard, MD, Selina Chen-Kiang, PhD

Blood (2011) 118 (21): 3738.

https://doi.org/10.1182/blood.V118.21.3738.3738

Published: 2011

Journal Articles

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma

Tomer M Mark, MD, MSc, Manan Shah, Melissa Rodriguez, Ryann Quinn, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Patrice Mignott, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 2937.

https://doi.org/10.1182/blood.V118.21.2937.2937

Published: 2011

Journal Articles

Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma

Ruben Niesvizky, MD, Luciano J Costa, MD, PhD, Nisreen A. Haideri, MD, Georg Hess, Seema Singhal, MD, Ivan Spicka, MD, PhD, Edward A. Stadtmauer, MD, Ashraf Z. Badros, MD, Marc S Raab, John L Jakubczak, PhD, Sindy T. Kim, BS, Sophia Randolph, MD, PhD, Scott A Ely, M.D., Selina Chen-Kiang, PhD

Blood (2011) 118 (21): 2940.

https://doi.org/10.1182/blood.V118.21.2940.2940

Published: 2011

Journal Articles

Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6

Xiangao Huang, PhD, Maurizio Di Liberto, Ph.D., Jamieson Bretz, Ph.D., David Chiron, PhD, Peter Martin, MD, Morton Coleman, MD, Jia Ruan, MD, PhD, Mitchell R Smith, MD, PhD, Scott A Ely, M.D., Christopher E. Mason, PhD, Phoebe Joy Ho, MBBS, DPhil, John P. Leonard, MD, Selina Chen-Kiang, PhD

Blood (2011) 118 (21): 1655.

https://doi.org/10.1182/blood.V118.21.1655.1655

Published: 2011

Journal Articles

A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Ruben Niesvizky, MD, Suzanne Lentzsch, MD, PhD, Ashraf Z. Badros, MD, Asher A. Chanan-Khan, MD, Seema B. Singhal, MD, Jeffrey A. Zonder, MD, Ravi Vij, MBBS, MD, Xiangao Huang, PhD, Maurizio DiLiberto, PhD, Rachel Courtney, PhD, M. Naveed Shaik, PhD, Sindy T. Kim, BS, Sophia Randolph, MD, PhD, Scott A Ely, MD, MPH, Selina Chen-Kiang, PhD

Blood (2010) 116 (21): 860.

https://doi.org/10.1182/blood.V116.21.860.860

Published: 2010

Journal Articles

MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells

Tricia Nardiello, BA, Achim A Jungbluth, MD, Anna Mei, BA, Maurizio DiLiberto, PhD, Xiangao Huang, PhD, Scott A Ely, MD, MPH, Ruben Niesvizky, MD, Morton Coleman, MD, Roger N Pearse, MD, PhD, David Jayabalan, B.S.M.S, Lloyd J Old, MD, Selina Chen-Kiang, PhD, Hearn J. Cho, MD, PhD

Blood (2010) 116 (21): 785.

https://doi.org/10.1182/blood.V116.21.785.785

Published: 2010

Journal Articles

Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization

Maurizio Di Liberto, Ph.D., Xiangao Huang, Ph.D., Jamieson Bretz, Ph.D., Scott A Ely, M.D., Rediet Zewdu, B.S., David Jayabalan, B.S.M.S, Suzhen Chen, B.S., Christopher J Kirk, Ph.D., Sophia Randolph, M.D., Ph.D., Ruben Niesvizky, M.D., Ph.D., Selina Chen-Kiang, Ph.D.

Blood (2010) 116 (21): 2989.

https://doi.org/10.1182/blood.V116.21.2989.2989

Published: 2010

Journal Articles

Myc Represses miR15a/Mir-16-1 Expression through Recruitment of HDAC3 In Mantle Cell Lymphoma

Xinwei Zhang, MD, Xia Chen, MD, Jianhong Lin, MD, Tint Lwin, MD, PhD, Scott A Ely, MD, Selina Chen-Kiang, MD, William S. Dalton, PhD, MD, Edward Seto, PhD, Kenneth Wright, PhD, Eduardo M. Sotomayor, MD, Jianguo Tao, MD, PhD

Blood (2010) 116 (21): 3121.

https://doi.org/10.1182/blood.V116.21.3121.3121

Published: 2010

Journal Articles

Updated Report of T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy for Upfront Use In Symptomatic Multiple Myeloma

Tomer M Mark, MD, MSc, Jennifer O'Loughlin, Morton Coleman, MD, David Jayabalan, B.S.M.S, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Scott A Ely, Megan Manco, Patrice Mignott, RN, John P. Leonard, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2010) 116 (21): 3050.

https://doi.org/10.1182/blood.V116.21.3050.3050

Published: 2010

Journal Articles

Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma

John P. Leonard, MD, Ann LaCasce, MD, Mitchell R Smith, MD, PhD, Ariela Noy, MD, Jeffrey T Yap, PhD, Annick D Van den Abbeele, MD, Jian Q Yu, MD, FRCPC, Selina Chen-Kiang, PhD, Scott A Ely, MD, PhD, Shankar Vallabhajosula, PhD, Lucian R Chirieac, MD, Steven M Larson, MD, Geoffrey I Shapiro, MD, PhD, Heiko Schoder

Blood (2008) 112 (11): 264.

https://doi.org/10.1182/blood.V112.11.264.264

Published: 2008

NARROW

The Ki67/CD138 Ratio Independently Predicts Overall Survival in the Upfront Treatment of Newly Diagnosed Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma

The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

Car-Bird [Carfilzomib, Clarithromycin(Biaxin (R) ), Lenalidomide/(Revlimid (R) ), Dexamethasone) For Newly-Diagnosed Multiple Myeloma

Integrative Whole Transcriptome and Exome Sequencing Reveals Reprogramming Of Mantle Cell Lymphoma In Prolonged Early G1 Arrest For Clinical Response To Selective Inhibition Of CDK4 In Combination Therapy

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Induction of Early G1-Arrest by CDK4/CDK6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to Selective PI3Kδ Inhibition by GS-1101 Through Enhancing the Magnitude and Duration of p-AKT Inhibition

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Mutation Burden in CDKN2C, CDK1 and E2F2 Is Associated with Differential Response to Targeting CDK4/CDK6 in Combination with Bortezomib in Mantle Cell Lymphoma,

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma

Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma

Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6

A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells

Induction of Metabolic Impairment In Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition Sensitizes Myeloma Cells for Proteasome Inhibitor Killing During Subsequent S Phase Synchronization

Myc Represses miR15a/Mir-16-1 Expression through Recruitment of HDAC3 In Mantle Cell Lymphoma

Updated Report of T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy for Upfront Use In Symptomatic Multiple Myeloma

Cdk4/6 Inhibitor PD 0332991 Demonstrates Cell Cycle Inhibition Via FLT-PET Imaging and Tissue Analysis in Patients with Recurrent Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only